IGC Pharma (IGC) Stock Price, News & Analysis

Company Overview

IGC Pharma, Inc. is a clinical-stage pharmaceutical company focused on developing cannabinoid-based therapies for neurological and neurodegenerative conditions. Its research programs target conditions including Alzheimer’s disease, dementia, pain, seizures, and other disorders affecting the central nervous system.

The company’s lead investigational product, IGC-AD1, is an oral formulation designed for the treatment of agitation associated with dementia related to Alzheimer’s disease. IGC Pharma has conducted clinical research on the product and continues to evaluate cannabinoid-based formulations through its pharmaceutical development programs.

In addition to its prescription-drug pipeline, the company has developed hemp-derived cannabinoid products marketed under the Holi Hemp brand. IGC Pharma is headquartered in Bethesda, Maryland, and is led by Chief Executive Officer Ram Mukunda. The company was formerly known as India Globalization Capital, Inc., reflecting its earlier focus on infrastructure and related business activities before its shift toward pharmaceutical and cannabinoid-based products.

Key Stats

• Today's Range: $0.24 to $0.26
• 50-Day Range: $0.25 to $0.33
• 52-Week Range: $0.24 to $0.45
• Volume: 405,402 shs
• Average Volume: 690,425 shs
• Market Capitalization: $25.43 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.50
• Consensus Rating: Moderate Buy

IGC Pharma Stock Analysis - MarketRank™

IGC Pharma scored higher than 58% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

IGC Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and no sell ratings.

Upside Potential

IGC Pharma has a consensus price target of $5.50, representing about 2,135.8% upside from its current price of $0.25.

Amount of Analyst Coverage

IGC Pharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for IGC Pharma are expected to grow in the coming year, from ($0.10) to ($0.08) per share.

Price to Book Value per Share Ratio

IGC Pharma has a P/B Ratio of 3.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.18% of the float of IGC Pharma has been sold short.

Short Interest Ratio / Days to Cover

IGC Pharma has a short interest ratio ("days to cover") of 1.44, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in IGC Pharma has recently decreased by 13.18%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

IGC Pharma does not currently pay a dividend.

Dividend Growth

IGC Pharma does not have a long track record of dividend growth.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: N/A

News Sentiment

IGC Pharma has a news sentiment score of -0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Healthcare companies.

Search Interest

1 people have searched for IGC on MarketBeat in the last 30 days.

MarketBeat Follows

4 people have added IGC Pharma to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, IGC Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

23.66% of the stock of IGC Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

3.87% of the stock of IGC Pharma is held by institutions.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 10/16/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NYSEAMERICAN:IGC
• Previous Symbol: NYSEMKT:IGC
• CIK: 1326205
• Web: www.igcinc.us
• Phone: (301) 529-4996
• Fax: 240-465-0273
• Employees: 70
• Year Founded: N/A

Price Target and Rating

• Average Price Target for IGC Pharma: $5.50
• High Price Target: $5.50
• Low Price Target: $5.50
• Potential Upside/Downside: +2,135.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.07)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -99.21%
• Return on Assets: -74.18%

Debt

• Debt-to-Equity Ratio: 0.02
• Current Ratio: 0.39
• Quick Ratio: 0.19

Sales & Book Value

• Annual Sales: $1.27 million
• Price / Sales: 20.02
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.08 per share
• Price / Book: 3.08

Miscellaneous

• Outstanding Shares: 103,380,000
• Free Float: 78,923,000
• Market Cap: $25.43 million
• Optionable: N/A
• Beta: 0.47